Merimepodib

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Merimepodib
File:Merimepodib structure.png
Legal status
Legal status
  • US: Investigational drug
Identifiers
  • [(3S)-oxolan-3-yl] N-[(3-{[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino}phenyl)methyl]carbamate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H24N4O6
Molar mass452.467 g·mol−1
3D model (JSmol)
  • COC1=C(C=CC(=C1)NC(=O)NC2=CC=CC(=C2)CNC(=O)O[C@H]3CCOC3)C4=CN=CO4
  • InChI=1S/C23H24N4O6/c1-30-20-10-17(5-6-19(20)21-12-24-14-32-21)27-22(28)26-16-4-2-3-15(9-16)11-25-23(29)33-18-7-8-31-13-18/h2-6,9-10,12,14,18H,7-8,11,13H2,1H3,(H,25,29)(H2,26,27,28)/t18-/m0/s1
  • Key:JBPUGFODGPKTDW-SFHVURJKSA-N

Merimepodib (VX-497) is a drug which acts as an inhibitor of the enzyme inosine monophosphate dehydrogenase, which is required for the synthesis of nucleotide bases containing guanine. This consequently inhibits synthesis of DNA and RNA, and results in antiviral and immunosuppressive effects.[1] It progressed as far as Phase 2b human clinical trials against hepatitis C, but showed only modest benefits in comparison to existing treatments;[2][3] however, it continued to be studied, and also shows activity against other viral diseases such as Zika virus and foot and mouth disease virus.[4][5]

Merimepodib was investigated in combination with remdesivir in a phase 2 clinical trial in the U.S. as a potential treatment of COVID-19 by ViralClear Pharmaceuticals.[6][7] The trial stopped in October 2020, and the company announced in a news release that it was "unlikely that the trial would meet its primary safety endpoints", and that it "does not intend to further develop merimepodib".[8]

References

[edit | edit source]
  1. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  4. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  5. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  6. ^ Clinical trial number NCT04410354 for "Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19 " at ClinicalTrials.gov
  7. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  8. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
Retrieved from "http://70.231.62.181/index.php?title=Merimepodib&oldid=20870038"